We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Drugs > Ustekinumab (Stelara) for psoriatic arthritis

< Back

Ustekinumab (Stelara) for psoriatic arthritis



September 2012

Ustekinumab (Stelara) is intended to be used for the treatment of psoriatic arthritis (PsA) in patients with structural joint damage after the failure of conventional disease modifying anti-rheumatic drugs (DMARDs). If licenced, it would provide an additional treatment option for this patient group. Ustekinumab is a human monoclonal antibody that targets the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), preventing their binding to receptors on T-cells and natural-killer cells. Ustekinumab is currently licensed in EU for the treatment of moderate to severe plaque psoriasis after failure of systemic therapies.
The prevalence of psoriasis in the general population is estimated at between 1.5-3%. The prevalence of inflammatory arthritis in people with psoriasis is estimated at ≤30%, however a prevalence of 50% has been recorded in some population studies. An estimated 5-10% of people with psoriasis and 25-40% of people with PsA have severe arthritis with progressive joint lesions. Joint damage has been shown radiologically in up to 47% of people with PsA at a median interval of 2 years. PsA can significantly affect the ability to work and to carry out daily tasks, which can have a substantial impact on quality of life. People with PsA have a 60% higher risk of mortality and their life expectancy is estimated to be reduced by approximately 3 years.
The clinical management of PsA includes physical therapy and a range of pharmacological treatments including DMARDs, such as methotrexate, and TNF alpha inhibitors. Ustekinumab is currently in two phase III clinical trials comparing its effect on ACR20 (a measure of improvement of arthritis) against treatment with placebo. These trials are expected to complete in 2012 and 2013.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts